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Ischemic preconditioning and the
risk of acute kidney injury
To the Editor: We have read with interest the paper by
Zimmerman et al.,1 in which the authors randomized to
either ischemic preconditioning or no intervention 120
patients undergoing cardiac surgery. The authors reported a
marked 57% lower risk for acute kidney injury (AKI) in
patients in whom preconditioning occurred.
Such a result may be partly explained by the study being
underpowered. The authors reported that a total of 120
subjects would provide 62% power to detect a 50% reduction
in the risk of AKI. The main concern with underpowered
studies is the increased risk of type II error (failing to reject a
false null hypothesis). However, an often underlooked pro-
blem arising from underpowered studies is the increased risk
of type I error (failing to reject a true null hypothesis).2 In
particular, simulation studies have shown how studies with
low power tend to yield incorrectly inﬂated effect size estimates.3
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The Authors Reply: We appreciate the opportunity to
address concerns regarding statistical power in our study.1
Ferraro and Gambaro’s2 statement that underpowered studies
are at increased risk for type I error is, in our opinion, an
oversimpliﬁcation of a rather complex issue. It can be argued
that equal P-values represent equal risks for type I error
regardless of sample size, or even that lower statistical power
strengthens the evidence represented by a given P-value and
reduces the likelihood of type I error.3 As we found an effect
of remote ischemic preconditioning that was highly statisti-
cally signiﬁcant (P¼ 0.004), we consider it improbable that
ours was a ‘false-positive’ study.
The authors raise the valid point that because small,
underpowered studies require more extreme results to reach
statistical signiﬁcance, they tend to overestimate effect size.
We regret not acknowledging this issue in our discussion of
limitations. Our a priori power analysis was based on pilot
data. If the observed data in our study are ‘true’, then the
power to detect the observed differences is substantially higher
than the 62% estimated before the study started, and is rather
83%. At 60% power, the simulation studies reported by
La Caze, et al.4 indicate that the probability of signiﬁcant result
bias is quite low, and at 80% power ‘shrinks to negligible
levels’. We therefore consider it unlikely that our ﬁndings are
seriously biased vis-a`-vis the effects of low statistical power.
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Biomarker for interstitial
inflammation
To the Editor: Zhang et al.1 have conducted a proof-of-
concept cross-sectional study on biomarkers of interstitial
inﬂammation in lupus nephritis. Although the authors allude
to biomarkers leading to a ‘continuous readout of kidney
pathology’, they use a dichotomous gold standard (none–mild
vs. moderate–severe interstitial inﬂammation on histology). It
would be more informative to observe the four groups
separately as classiﬁed by the blinded nephropathologist. Was
there a gradient (dose–response) in the levels of biomarkers in
the four groups of none, mild, moderate, and severe? This
may not be ‘clinically signiﬁcant’ but will increase conﬁdence
in the result.
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Second, could these markers actually be reﬂecting
glomerular inﬂammation? Severe interstitial inﬂammation is
more commonly associated with class III or IV.2 Even in this
study, 11/12 (92%) class II and class V biopsies, 11/15 (73%)
class III (or IIIþV) biopsies, and 25/37 (68%) class IV
biopsies had none–mild interstitial inﬂammation. Thus, there
is a need to adjust for severity of glomerular disease. It will be
interesting to know the performance of these biomarkers
looking at class III and class IV only, and with regard to the
activity index (sans interstitial inﬂammation). Only then
perhaps can we be sure that they truly represent interstitial
inﬂammation.
Third, they have talked about biomarkers being used
‘following therapy of lupus nephritis’ and to ‘individualize
treatment decisions’. Indeed, a biomarker of interstitial
inﬂammation (and ﬁbrosis) may have prognostic signiﬁ-
cance.2 However, therapy and indeed our classiﬁcation
systems continue to focus on glomerular inﬂammation.3,4
Thus, unless interstitial inﬂammation itself is incorporated
into classiﬁcation and becomes a guide to therapy, it is
unlikely that a biomarker of the same will help make treat-
ment decisions.
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The Authors Reply: Dr Dhir1 raises several interesting
points concerning our recent publication on biomarkers of
tubulointerstitial injury in lupus nephritis (LN)2 that support
the potential clinical utility of these biomarker equations.
Our responses in order are as follows: (1) The biomarker
equations are intended to provide a readout of kidney
pathology continuously in real time to follow the response of
the tubulointerstitium to therapy. (2) To examine speciﬁcity
of the biomarker equations for the tubulointerstitium as
opposed to the glomeruli, we tested the ability of the inﬂam-
mation equation (equation 1) to determine the presence or
absence of glomerular endocapillary proliferation (39% mis-
classiﬁed) and the presence of crescents/necrosis in410% of
glomeruli (33% misclassiﬁed). The ﬁbrosis equation (equation
2) was used to identify biopsies having glomerulosclerosis in
425% of glomeruli (28% misclassiﬁed). These results are
not unexpected, because although lesions in the glomerular
and interstitial compartments are correlated, the correlations
are weak to moderate.3 However, the biomarkers used to
derive equations 1 and 2 appear to also be relevant for
glomerular pathologies, but will require different optimization
of weighting and cutoffs. Such optimization can readily
be accomplished using discriminant analysis, illustrating
the applicability of this technique for biomarker develop-
ment in LN and other kidney diseases. (3) Despite current
glomerulocentric classiﬁcations of LN, it is well recognized
that chronic tubulointerstitial damage determines long-term
renal prognosis,4 and therapeutic targeting of tubulointer-
stitial injury does not necessarily need to wait until
classiﬁcation schemes better acknowledge the importance of
the tubulointerstitium.
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Laparoscopic approach for the
evaluation of peritoneal injury
To the Editor: Encapsulating peritoneal sclerosis (EPS) is a
severe complication of long-term peritoneal dialysis (PD)
with a high mortality rate. EPS is characterized by a progres-
sive inﬂammatory process resulting in the development of
intra-abdominal ﬁbrosis that envelops and constricts the
viscera, thereby compromising the motility and function of
the intestine, leading to partial and complete intestinal
obstruction.
Takara and Ishibashi1 reported that an endoscopy could be
used for the treatment for obstructed peritoneal catheter. Here
we used an endoscope for the diagnosis of EPS. We used a
laparoscopic approach for the evaluation of peritoneal injury
in PD patients. The peritoneum of a 64-year-old woman who
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